Compare GSM & MLTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GSM | MLTX |
|---|---|---|
| Founded | 2015 | 2021 |
| Country | United Kingdom | Switzerland |
| Employees | N/A | N/A |
| Industry | Metal Mining | Biotechnology: Pharmaceutical Preparations |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 920.1M | 979.8M |
| IPO Year | N/A | N/A |
| Metric | GSM | MLTX |
|---|---|---|
| Price | $4.81 | $15.76 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 2 | 9 |
| Target Price | $6.00 | ★ $22.22 |
| AVG Volume (30 Days) | 1.1M | ★ 3.6M |
| Earning Date | 02-18-2026 | 02-25-2026 |
| Dividend Yield | ★ 1.15% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $1,373,244,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $22.56 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $2.97 | $5.95 |
| 52 Week High | $5.74 | $62.75 |
| Indicator | GSM | MLTX |
|---|---|---|
| Relative Strength Index (RSI) | 47.27 | 52.85 |
| Support Level | $4.86 | $15.20 |
| Resistance Level | $5.30 | $16.57 |
| Average True Range (ATR) | 0.25 | 1.19 |
| MACD | -0.04 | -0.06 |
| Stochastic Oscillator | 12.59 | 22.36 |
Ferroglobe PLC provides silicon-based alloys and specialty metals. It produces silicon metal and silicon and manganese-based alloy, serving customers in the specialty chemical, aluminum, solar, steel, and ductile iron foundry industries. The company's business segments include North America- Silicon, North America -Silicon Alloys; Europe Manganese; Europe Silicon Metals; Europe -Silicon Alloys, South Africa Silicon Metals, South Africa-Silicon Alloys, and Other segments The primary raw materials company uses to produce its electrometallurgy products includes its coal and quartz mining operations and its silicon metal and ferroalloy production.
MoonLake Immunotherapeutics is a clinical-stage biotechnology company advancing therapies to address unmet needs in inflammatory skin and joint diseases. The company is focused on the development of SLK, a novel tri-specific IL-17A and IL-17F inhibiting Nanobody that has the potential, based on response levels seen in clinical trials, to drive disease modification in dermatology and rheumatology patients.